Lerner Yu V, Tsoy L V, Grishina A N, Varshavsky V A
I.M. Sechenov First Moscow State Medical University (Sechenov University) Ministry of Health of Russia, Moscow, Russia.
Arkh Patol. 2022;84(1):21-26. doi: 10.17116/patol20228401121.
Fabry disease is an X-linked progressive lysosomal disease caused by a mutation in the gene that encodes the enzyme alpha-galactosidase A and leads to the intracellular accumulation of globotriazylceramide (GL-3). Kidney damage manifested itself as microproteinuria and microalbuminuria, followed by renal failure, is fatal to a patient.
Fabry disease was diagnosed in 5 out of 600 cases of various kidney diseases, by using the 2014-2018 material. Light-optical, immunohistochemical, and electron microscopy methods were used to examine kidney biopsy specimens in Fabry disease.
The glomeruli clearly exhibited intralysosomal inclusions, myelin bodies, and fatty vacuoles in the cytoplasm of podocytes, the small processes of which were predominantly reduced. The mesangial space was expanded; the mesangiocytes were in the proliferation state; there were fatty vacuoles in the cytoplasm; the deposits of immune complexes located intramembranously and paramesangially were also found in all cases. An immunohistochemical study revealed that each case was detected to have fixations of IgG, kappa and lambda immunoglobulin chains on the glomerular basement membrane of focal granular pattern. There was fixation of fibrinogen in 3 cases, that of IgM in 2 cases, and that of IgA and complement component 3 in one case. Thus, it can be supposed that although Fabry disease is a lysosomal disease with deposits in the podocytes and mesangiocytes of myelin bodies and fatty vacuoles; however, immunohistochemical and electron microscopic studies cannot exclude the involvement of immune processes in the development of glomerular injury.
Fabry disease is a rare lysosomal disease accompanied by globotriazylceramide deposits in the podocytes and mesangiocytes. However, at the same time, the fact that immune mechanisms are involved in the development of this disease cannot be denied.
法布里病是一种X连锁进行性溶酶体疾病,由编码α-半乳糖苷酶A的基因突变引起,导致球三己糖神经酰胺(GL-3)在细胞内蓄积。肾脏损害表现为微量蛋白尿和微量白蛋白尿,随后发展为肾衰竭,对患者来说是致命的。
利用2014 - 2018年的材料,在600例各种肾脏疾病患者中,有5例被诊断为法布里病。采用光学显微镜、免疫组织化学和电子显微镜方法对法布里病患者的肾脏活检标本进行检查。
肾小球明显表现出溶酶体内包涵体、髓样小体以及足细胞胞质内的脂肪空泡,足细胞的小突起明显减少。系膜间隙增宽;系膜细胞处于增殖状态;胞质内有脂肪空泡;所有病例均发现免疫复合物沉积于膜内和系膜旁。免疫组织化学研究显示,每例均在肾小球基底膜上检测到局灶颗粒状的IgG、κ和λ免疫球蛋白链固定。3例有纤维蛋白原固定,2例有IgM固定,1例有IgA和补体成分3固定。因此,可以推测,尽管法布里病是一种溶酶体疾病,在足细胞和系膜细胞中有髓样小体和脂肪空泡沉积;然而,免疫组织化学和电子显微镜研究不能排除免疫过程参与肾小球损伤的发生。
法布里病是一种罕见的溶酶体疾病,伴有球三己糖神经酰胺在足细胞和系膜细胞中的沉积。然而,与此同时,不能否认免疫机制参与了该疾病的发生这一事实。